Eli Lilly and Company (LLY)

$762.73 -22.30 (-2.84%)
Market Cap 744.00B
Revenue (ttm) 45.04B
Net Income (ttm) 10.59B
EPS (ttm) N/A
PE Ratio 57.50
Forward PE 35.77
Profit Margin 23.51%
Debt to Equity Ratio 2.18
Volume 6,210,600
Avg Vol 4,236,036
Day's Range N/A - N/A
Shares Out 947.74M
Stochastic %K 10%
Beta 0.40
Analysts Strong Sell
Price Target $983.12

Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncolog...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 317 276 2000
Address:
Lilly Corporate Center, Indianapolis, United States
Wallst45
Wallst45 Jun. 21 at 11:41 AM
$NVO results from Phase 3b STEP UP trial showed that higher dose of Wegovy (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight vs. placebo. $LLY $VKTX #ADA25
0 · Reply
BioRich
BioRich Jun. 21 at 3:18 AM
$REGN If I'm not mistaken, this is 1 of 3 shots on goal (FDA PDUFA) $REGN has in the next month or so. Looks like a great start. Anyone have color on what they think the TAM is for this approval? Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $LLY $SNY $CRVS
1 · Reply
biolover
biolover Jun. 21 at 1:01 AM
$VKTX From the second lancet paper addressing $NVO oral amycretin , this time in SA and not from Japan. One can contrast the rate of vomiting ( this time zero in placebo and highest with twice daily dose ) and what was reported in $VKTX oral VK2735 phase 1. Also the wt loss here is deeper with 25 mg bid vs 50 mg qd correlating with higher vomiting in bid dose. Also wt rebound quickly after last dose vs wt loss maintenance for extra month in vk2735. All point to GLP1-GIP as primary regulator of po intake uncoupled from vomiting vs amylin adding to GLP1 toxicity. $LLY $PFE
2 · Reply
biolover
biolover Jun. 21 at 12:36 AM
$VKTX $NVO $LLY Amycretin data not looking good . Just published in lancet. weird phase 1 design. No dose response as below , 20 mg curve overlaps with 1.25 mg curve. Vomiting all over the place including in placebo. Single site in San Antonio. They utilized anti emetics extensively. Is this what nivo has for Lilly long term?. All eggs now in 9542-NN130 trial basket. Way over due for results. ?
1 · Reply
vastav
vastav Jun. 21 at 12:13 AM
$LLY seems like 700 possible next week
0 · Reply
Ro_Patel
Ro_Patel Jun. 21 at 12:05 AM
Now: President Trump & his associates have repeatedly criticized companies’ moves to offshore much drug making, particularly to Ireland. “We can’t be beholden & rely upon foreign countries for fundamental things that we need” Commerce Secretary Lutnick said on April 13 Then: But the tax incentives in President Trump’s 2017 tax & spending package helped generate this problem in the 1st place — a problem that would continue under the bill under consideration Republicans tend to blame Ireland’s lower corporate tax rate for the proliferation of corporate tax avoidance, but the real incentive comes from this obscure corner of the tax code. It offers a far-lower 10.5% tax rate for global profits if a global firm moves the profits from its IP offshore. The tax rate for domestic profits, in contrast, is 21% The tax break was created by Republicans Unsurprisingly, America’s imports of pharmaceuticals soaring to $250B in 2024, way up from $110B back in 2016 $XLV $PFE $JNJ $LLY - $AAPL
2 · Reply
jgreenstein3412
jgreenstein3412 Jun. 20 at 11:51 PM
$LLY almost down 6 percent on buyout news we getting ready for prime run up due
0 · Reply
jgreenstein3412
jgreenstein3412 Jun. 20 at 11:50 PM
$LLY almost perfect set up let her drop 4% for start of entry at 750 .. next week will be choppy till news in middle East calms down
0 · Reply
StrayTrader
StrayTrader Jun. 20 at 9:28 PM
$LLY I think today’s decline had more to do with options expiration than with the U.K. decision on the Alzheimer’s treatment. Look at a 5 day chart … it was already on a steady downtrend.
1 · Reply
Brokie4eva
Brokie4eva Jun. 20 at 8:06 PM
$LLY bought calls but might be a mistake. It fell before close. Thats not good. Hopefully some good news come soon.
0 · Reply
Latest News on LLY
Final Trade: LLY, SHEL, USO, WMT

Jun 20, 2025, 6:21 PM EDT - 14 hours ago

Final Trade: LLY, SHEL, USO, WMT

WMT SHEL USO

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

Jun 20, 2025, 3:45 PM EDT - 17 hours ago

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

NVO

3 'Underdog Stocks' For The Rest Of 2025

Jun 20, 2025, 2:23 PM EDT - 18 hours ago

3 'Underdog Stocks' For The Rest Of 2025

CNC WEN

This AI Trader Bought Meta Stock and Dumped Eli Lilly

Jun 20, 2025, 6:34 AM EDT - 1 day ago

This AI Trader Bought Meta Stock and Dumped Eli Lilly

META

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand

Jun 20, 2025, 4:51 AM EDT - 1 day ago

Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

Jun 18, 2025, 11:28 PM EDT - 2 days ago

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

VERV

Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug

Jun 18, 2025, 7:08 PM EDT - 2 days ago

Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

Jun 18, 2025, 10:47 AM EDT - 2 days ago

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

SRRK

Beyond Obesity: Eli Lilly's Genetic Medicine Bet On Verve Therapeutics

Jun 18, 2025, 8:55 AM EDT - 3 days ago

Beyond Obesity: Eli Lilly's Genetic Medicine Bet On Verve Therapeutics

Lilly to buy gene-editing partner Verve for $1.3 billion

Jun 17, 2025, 12:57 PM EDT - 3 days ago

Lilly to buy gene-editing partner Verve for $1.3 billion

VERV

Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound

Jun 17, 2025, 11:39 AM EDT - 3 days ago

Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound

JBLU Cutting Back Flights, Solar Stocks Sell, LLY Bid for VERV

Jun 17, 2025, 10:30 AM EDT - 3 days ago

JBLU Cutting Back Flights, Solar Stocks Sell, LLY Bid for VERV

FSLR JBLU RUN VERV ENPH JETS SEDG

Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)

Jun 17, 2025, 8:46 AM EDT - 4 days ago

Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)

This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly

Jun 17, 2025, 8:13 AM EDT - 4 days ago

This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

Jun 17, 2025, 7:55 AM EDT - 4 days ago

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

VERV

Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say

Jun 17, 2025, 6:54 AM EDT - 4 days ago

Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say

VERV

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

Jun 17, 2025, 6:45 AM EDT - 4 days ago

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

VERV

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%.

Jun 17, 2025, 5:33 AM EDT - 4 days ago

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%.

VERV

Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports

Jun 16, 2025, 7:49 PM EDT - 4 days ago

Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports

VERV

Lilly to offer higher dose versions of weight-loss drugs on website

Jun 16, 2025, 7:04 AM EDT - 5 days ago

Lilly to offer higher dose versions of weight-loss drugs on website

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions

Jun 16, 2025, 6:45 AM EDT - 5 days ago

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions

Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial

Jun 13, 2025, 6:44 PM EDT - 7 days ago

Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial

Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock

Jun 13, 2025, 10:47 AM EDT - 7 days ago

Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock

Healthy Returns: Ozempic, Wegovy linked to rare cases of serious eye condition

Jun 11, 2025, 2:00 PM EDT - 9 days ago

Healthy Returns: Ozempic, Wegovy linked to rare cases of serious eye condition

NVO

Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health

Jun 11, 2025, 7:30 AM EDT - 10 days ago

Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health

Drug pricing reform talks with US government lack clarity, industry executives say

Jun 10, 2025, 2:03 PM EDT - 10 days ago

Drug pricing reform talks with US government lack clarity, industry executives say

MRK

Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 10, 2025, 10:14 AM EDT - 10 days ago

Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

The Highest-Quality Dividend Contenders By Quality Scores

Jun 10, 2025, 9:00 AM EDT - 11 days ago

The Highest-Quality Dividend Contenders By Quality Scores

AAPL ABT ACN AMP AON CASS CMCSA

20 stocks of companies that have improved profit margins and are expected to grow quickly

Jun 9, 2025, 9:28 AM EDT - 11 days ago

20 stocks of companies that have improved profit margins and are expected to grow quickly

AMD AVGO CSGP DASH ENPH FICO FTNT

Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?

Jun 6, 2025, 4:08 PM EDT - 14 days ago

Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?

ABBV ABT JNJ UNH XLV

Rare Outflow Signals Hit Eli Lilly Shares

Jun 6, 2025, 6:38 AM EDT - 15 days ago

Rare Outflow Signals Hit Eli Lilly Shares

Lilly's Jake Van Naarden: Lilly's success with GLP-1's allows us to reinvest in oncology

Jun 5, 2025, 9:39 AM EDT - 15 days ago

Lilly's Jake Van Naarden: Lilly's success with GLP-1's allows us to reinvest in oncology

Welldoc Works with Lilly to Launch a New Personalized Health & Medicine Platform for Those Prescribed Lilly's Incretin Therapies

Jun 4, 2025, 10:00 AM EDT - 16 days ago

Welldoc Works with Lilly to Launch a New Personalized Health & Medicine Platform for Those Prescribed Lilly's Incretin Therapies

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Jun 3, 2025, 2:12 PM EDT - 17 days ago

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Top 50 High-Quality Dividend Stocks For June 2025

Jun 3, 2025, 12:53 PM EDT - 17 days ago

Top 50 High-Quality Dividend Stocks For June 2025

AAPL ACN ALLE AMAT APH CTAS DHI

LLY Stock Too Cheap At $750?

Jun 3, 2025, 8:55 AM EDT - 18 days ago

LLY Stock Too Cheap At $750?

Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades

Jun 2, 2025, 11:00 AM EDT - 18 days ago

Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades

JNJ ABVX

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

Jun 2, 2025, 10:00 AM EDT - 18 days ago

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way

Jun 2, 2025, 8:14 AM EDT - 19 days ago

Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Jun 2, 2025, 8:00 AM EDT - 19 days ago

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Eli Lilly Rises 1.5% After Key Trading Signal

Jun 2, 2025, 7:15 AM EDT - 19 days ago

Eli Lilly Rises 1.5% After Key Trading Signal

5 Alpha Generating Monsters

May 30, 2025, 10:32 AM EDT - 21 days ago

5 Alpha Generating Monsters

APO COKE ENVA FICO

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions

May 29, 2025, 5:00 PM EDT - 22 days ago

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions

Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternatives

May 27, 2025, 3:32 PM EDT - 24 days ago

Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternatives

Eli Lilly to acquire privately held SiteOne

May 27, 2025, 10:09 AM EDT - 24 days ago

Eli Lilly to acquire privately held SiteOne

Weight-loss drugs like Ozempic and Wegovy continue to be in high demand—and expensive. Are prices likely to come down soon?

May 27, 2025, 10:00 AM EDT - 24 days ago

Weight-loss drugs like Ozempic and Wegovy continue to be in high demand—and expensive. Are prices likely to come down soon?

NVO

Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics

May 27, 2025, 10:00 AM EDT - 24 days ago

Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics

Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 5:05 PM EDT - 4 weeks ago

Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs

May 21, 2025, 4:37 PM EDT - 4 weeks ago

Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs

CI NVO

Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease

May 21, 2025, 4:21 PM EDT - 4 weeks ago

Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease

Wallst45
Wallst45 Jun. 21 at 11:41 AM
$NVO results from Phase 3b STEP UP trial showed that higher dose of Wegovy (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight vs. placebo. $LLY $VKTX #ADA25
0 · Reply
BioRich
BioRich Jun. 21 at 3:18 AM
$REGN If I'm not mistaken, this is 1 of 3 shots on goal (FDA PDUFA) $REGN has in the next month or so. Looks like a great start. Anyone have color on what they think the TAM is for this approval? Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $LLY $SNY $CRVS
1 · Reply
biolover
biolover Jun. 21 at 1:01 AM
$VKTX From the second lancet paper addressing $NVO oral amycretin , this time in SA and not from Japan. One can contrast the rate of vomiting ( this time zero in placebo and highest with twice daily dose ) and what was reported in $VKTX oral VK2735 phase 1. Also the wt loss here is deeper with 25 mg bid vs 50 mg qd correlating with higher vomiting in bid dose. Also wt rebound quickly after last dose vs wt loss maintenance for extra month in vk2735. All point to GLP1-GIP as primary regulator of po intake uncoupled from vomiting vs amylin adding to GLP1 toxicity. $LLY $PFE
2 · Reply
biolover
biolover Jun. 21 at 12:36 AM
$VKTX $NVO $LLY Amycretin data not looking good . Just published in lancet. weird phase 1 design. No dose response as below , 20 mg curve overlaps with 1.25 mg curve. Vomiting all over the place including in placebo. Single site in San Antonio. They utilized anti emetics extensively. Is this what nivo has for Lilly long term?. All eggs now in 9542-NN130 trial basket. Way over due for results. ?
1 · Reply
vastav
vastav Jun. 21 at 12:13 AM
$LLY seems like 700 possible next week
0 · Reply
Ro_Patel
Ro_Patel Jun. 21 at 12:05 AM
Now: President Trump & his associates have repeatedly criticized companies’ moves to offshore much drug making, particularly to Ireland. “We can’t be beholden & rely upon foreign countries for fundamental things that we need” Commerce Secretary Lutnick said on April 13 Then: But the tax incentives in President Trump’s 2017 tax & spending package helped generate this problem in the 1st place — a problem that would continue under the bill under consideration Republicans tend to blame Ireland’s lower corporate tax rate for the proliferation of corporate tax avoidance, but the real incentive comes from this obscure corner of the tax code. It offers a far-lower 10.5% tax rate for global profits if a global firm moves the profits from its IP offshore. The tax rate for domestic profits, in contrast, is 21% The tax break was created by Republicans Unsurprisingly, America’s imports of pharmaceuticals soaring to $250B in 2024, way up from $110B back in 2016 $XLV $PFE $JNJ $LLY - $AAPL
2 · Reply
jgreenstein3412
jgreenstein3412 Jun. 20 at 11:51 PM
$LLY almost down 6 percent on buyout news we getting ready for prime run up due
0 · Reply
jgreenstein3412
jgreenstein3412 Jun. 20 at 11:50 PM
$LLY almost perfect set up let her drop 4% for start of entry at 750 .. next week will be choppy till news in middle East calms down
0 · Reply
StrayTrader
StrayTrader Jun. 20 at 9:28 PM
$LLY I think today’s decline had more to do with options expiration than with the U.K. decision on the Alzheimer’s treatment. Look at a 5 day chart … it was already on a steady downtrend.
1 · Reply
Brokie4eva
Brokie4eva Jun. 20 at 8:06 PM
$LLY bought calls but might be a mistake. It fell before close. Thats not good. Hopefully some good news come soon.
0 · Reply
ZacksResearch
ZacksResearch Jun. 20 at 7:59 PM
$LLY or $ABBV: Which Pharma Giant Should You Bet On? 💊💥 Eli Lilly's overall business expects a 32% revenue growth for 2025, fueled by its diverse drug portfolio, including GLP-1 drugs, Mounjaro and Zepbound. Yet, AbbVie, with its strong Skyrizi and Rinvoq sales and a cheaper valuation, looks like a safer bet for short-term investors, boasting a 3.5% dividend yield and projected mid-single-digit revenue growth in 2025. 📈💰 Discover the full comparison and insights here 👉 https://www.zacks.com/commentary/2519897/lly-vs-abbv-which-pharma-powerhouse-is-the-better-bet?cid=sm-stocktwits-2-2519897-body&ADID=SYND_STOCKTWITS_TWEET_2_2519897_BODY
1 · Reply
walkinghome
walkinghome Jun. 20 at 7:13 PM
$LLY $NVO $VKTX $ALT i suspect promising obesity drugs like viking will be in line for fastrack. Not only to help america's health crisis. but to put competition in the market.
2 · Reply
clan
clan Jun. 20 at 7:11 PM
$MNKD All the $NVO $LLY $SNY folks at the ADA conference, this weekend in Chicago, are going to leave knowing about Afrezza, ... and ... they're gonna want a piece of that tasty goodness. 🚫💉 🇺🇸💪 Ingnore the trolls.
1 · Reply
Ro_Patel
Ro_Patel Jun. 20 at 6:45 PM
American College of Cardiology: Weight-loss drugs should be used earlier, making them part of the first line of defense for obese patients. Millions more Americans should be taking weight-loss drugs to prevent heart disease The ACC’s recommendation is a departure from its previous recommendation that advocated for lifestyle modifications before obesity medications. The new guidelines may have sweeping public health and policy implications that could reduce damage from heart disease Uncertainty about insurance coverage is a significant barrier to treatment, the ACC said, noting there is “ongoing need to improve access to these therapies.” CDC: More than 40% of adults in the US are obese $LLY $NVO $VKTX $ALT
1 · Reply
OGDollaFieldz
OGDollaFieldz Jun. 20 at 6:13 PM
$LLY --- Finally broke (a lil bit) Now, lets see how she sets up for next week...
0 · Reply
clan
clan Jun. 20 at 5:50 PM
$MNKD Diabetics are DEMANDING Afrezza! Weekly Revenues rise, week over week! Git ya some $SNY $LLY $NVO with partnership? Best TIR !
0 · Reply
PubCoInsight_
PubCoInsight_ Jun. 20 at 5:22 PM
⚔️ A two-week pause in Middle East tensions… or just the eye of the storm? Trump hits pause, oil dips, Europe rises—and Wall Street watches. Don’t mistake calm for peace. 📲 Read the full breakdown: https://pubcoinsight.com/markets-hold-their-breath-geopolitics-capital-shifts-the-quiet-storm-beneath-the-surface/ $GOOG $META $LLY #Geopolitics #Oil #Stocks
0 · Reply
BioRich
BioRich Jun. 20 at 4:22 PM
$PRTA Happily doubled my position here. Lucky to load up on this gem. Foresee exciting short-term and long-term potential here. Recent pull back allows for tremendous investment here. Lots of shots on goal and appears to be a winner. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $PFE $GILD $LLY
0 · Reply
Keepitmoving
Keepitmoving Jun. 20 at 4:15 PM
$LLY who cares about the UK. That’s a single payer system with ultra low pricing needed for reimbursement. Not at all an important market, like the US.
0 · Reply
Brokie4eva
Brokie4eva Jun. 20 at 4:14 PM
$LLY not a too bad news just volatile. Im watching to see if I’m going to buy calls for next week.
0 · Reply
vastav
vastav Jun. 20 at 4:05 PM
$LLY not interesting. In bear market now.
0 · Reply
StrayTrader
StrayTrader Jun. 20 at 3:45 PM
$LLY none of the Alzheimer’s drugs actually work, so the U.K. action shouldn’t surprise anyone. But you buy this here for the the whole class of weight loss / diabetes / GLP-1 drugs.
1 · Reply